The landmark Health Technology Assessment (HTA) Regulation and the EU-level joint clinical assessments (JCAs) that represent a huge shift in the region’s pricing and reimbursement landscape became applicable on 12 January. The pharmaceutical industry says that any kinks in the new system must be ironed out as quickly as possible, even ahead of the 2028 planned review of the procedures.
Game-Changing EU-Level HTA Regs Must Allow For Lessons To Be Learned
EU joint clinicals assessments introduced under the HTA Regulation have now gone live for cancer medicines and advanced therapies.
